Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 11.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 88,898 shares of the biopharmaceutical company’s stock after purchasing an additional 8,908 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Royalty Pharma were worth $2,497,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RPRX. M&T Bank Corp grew its position in Royalty Pharma by 2.5% in the third quarter. M&T Bank Corp now owns 10,671 shares of the biopharmaceutical company’s stock valued at $428,000 after acquiring an additional 259 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Royalty Pharma by 7.3% in the second quarter. PNC Financial Services Group Inc. now owns 4,973 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 337 shares in the last quarter. Advisor Group Holdings Inc. grew its position in Royalty Pharma by 9.4% in the first quarter. Advisor Group Holdings Inc. now owns 4,265 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 366 shares in the last quarter. Sei Investments Co. grew its position in Royalty Pharma by 4.7% in the first quarter. Sei Investments Co. now owns 8,392 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 379 shares in the last quarter. Finally, Virtu Financial LLC grew its position in Royalty Pharma by 5.8% in the fourth quarter. Virtu Financial LLC now owns 7,604 shares of the biopharmaceutical company’s stock valued at $300,000 after acquiring an additional 417 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RPRX. Bank of America lowered their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 11th. The Goldman Sachs Group lowered their price objective on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. reduced their target price on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a research note on Tuesday, February 20th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Royalty Pharma has a consensus rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $27.89 on Friday. The stock has a market cap of $16.66 billion, a P/E ratio of 14.76, a price-to-earnings-growth ratio of 0.78 and a beta of 0.45. The company has a current ratio of 7.90, a quick ratio of 7.90 and a debt-to-equity ratio of 0.61. The stock has a 50 day moving average of $29.79 and a 200-day moving average of $28.50. Royalty Pharma plc has a 52 week low of $25.92 and a 52 week high of $36.48.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.03 by $0.12. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. The company had revenue of $736.00 million during the quarter, compared to analysts’ expectations of $702.90 million. On average, analysts expect that Royalty Pharma plc will post 3.95 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 3.01%. The ex-dividend date is Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 44.44%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.